Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search

New İndication: Trastuzumab deruxtecan in patients with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after trastuzumab-containing regimen

New İndication: Trastuzumab deruxtecan in patients with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after trastuzumab-containing regimen
Study:
  • Single-arm, multicenter, phase II trial
  • HER2 positive, unresectable or metastatic gastric or gastro-esophageal junction cancer, progressive disease on or after first-line therapy with a trastuzumab-containing regimen
  • Trastuzumab-deruxtecan (n=79)
Efficacy:
  • cORR: 42% [33 of 79 pts]
  • CR: 5% [ 4 of 79 pts]
  • mPFS: 5.6 mos [4.2-8.3]
  • mOS: 12.1 mos [9.4-15.4]
  • mDoR: 8.1 mos [5.9-NR]
Safety:
  • Grade≥3: Anemia (14%), nausea (8%), neutropenia (8%)

LANCET Oncol, VOL 24, ISSUE 7, P744-756, JUL 2023

Cutsem Eric Van et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

http://doi.org/10.1016/S1470-2045(23)00215-2

Reviewed by Elvin CHALABİYEV, MD on AUG 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More